Status quo: Crohn's and Colitis biomarkers

Conventional serum calprotectin biomarkers are often not as clinically useful as the fecal versions, which is related to the half-life of calprotectin in blood (only 5-6 hours), leading to dissociation of calprotectin protein. The short half-life of calprotectin in blood reduces the window in which the current serum calprotectin ELISA assay can detect calprotectin dimer protein, which is composed of monomers S100A8 and S100A9.

By applying the Protein Fingerprint technology, we have identified a neo-epitope of the S100A9 monomer of calprotectin derived from proteolytic cleavage by human neutrophil elastase (HNE). This ELISA assay is referred to as the CPa9-HNE assay and is a new and innovative method for quantification of calprotectin in serum developed by Nordic Bioscience.


Inflammatory Bowel Disease (IBD) flares in the intestines.

A new tool to measure... calprotectin

The CPa9-HNE assay was initially demonstrated to have significantly higher serum levels in patients with Crohn's disease and ulcerative colitis are significantly higher than in healthy subjects (HS). (CD: AUC: 0.98 (CI: 0.97-1.00), p < 0.0001) and (UC: AUC: 0.96 (CI: 0.92-1.00), p < 0.0001) patients compared to the HS).

CPa9-HNE showed better separation between IBD patients and HS than the MRP8/14 serum calprotectin assay from the Bühlmann lab. (UC: AUC: 0.72 (CI: 0.59-0.86), p = 0.0025) and (CD: AUC: 0.70 (CI: 0.56–0.84), p = 0.0046) compared with the HS.

In this study, the CPa9-HNE biomarker showed better correlation with the endoscopic score for Crohn's disease (SES-CD) and ulcerative colitis (MES) than the FCP. The MRP8/14 assay and neutrophil count showed no significant correlation with endoscopic scores for IBD patients.

To investigate the diagnostic accuracy of the CPa9-HNE received operator characteristic curve was performed, demonstrating CPa9-HNE with acceptable diagnostic accuracy to identify patients with IBD in remission vs. active (SES-CD: AUC=0.68, p=0.0149; full mayo score: AUC=0.82, p=0.0036) and patients in remission vs. moderate/severe disease activity active (SES-CD: AUC=0.85, p=0.0002; full mayo score: AUC=0.94, p=0.0021).

Finally, we demonstrated that the CPa9-HNE biomarker could detect the calprotectin neo-epitope only in the supernatant of in vitro activated primary human neutrophils, but not in inactive primary human neutrophils. This was in contrast to the MRP8/14 serum CP assay of the Bühlmann lab, as both inactive and activated primary human neutrophils secreted detectable levels of calprotectin.

CPa9-HNE ELISA proved to be a novel serum calprotectin biomarker with significant clinical potential as a biomarker for patients with IBD to monitor disease activity and neutrophil activity.

However, circulating calprotectin metabolites released from locally inflamed mucosa are not be dissociated further. They can be readily quantified using an ELISA-based technique called Protein Fingerprint technology. This refined ELISA technique quantifies protein metabolites or neo-epitopes derived from proteolysis that reflect local tissue inflammation and remodeling.

Read the full article here.

Please don't hesitate to contact us if you have any questions or other inquiries.

Please don't hesitate to contact us if you have any questions or other inquiries.